» Articles » PMID: 16515689

Influence of Liver Cancer on Lipid and Lipoprotein Metabolism

Overview
Publisher Biomed Central
Date 2006 Mar 7
PMID 16515689
Citations 76
Authors
Affiliations
Soon will be listed here.
Abstract

Liver plays a key role in the metabolism of plasma apolipoproteins, endogenous lipids and lipoproteins. Hepatocellular carcinoma (HCC) is one of the most common fatal malignant tumors in China and in other Southeast Asian countries. This has been attributed to the high incidence of hepatitis B infection. Hepatitis B proteins, such as the hepatitis B X protein (HBx) that is large hepatitis B surface protein could regulate transcription of many candidate genes for liver carcinogenesis. It has known that patients who suffered from acute hepatitis B could have lipid disorders such as decreased plasma level of high-density lipoproteins (HDL). Furthermore, aberrations of lipid metabolism are often seen in the chronic hepatitis B infection. Plasma lipid profiles could be changed under HCC. In majority of the reports in HCC, plasma levels of triglycerides (TG), cholesterol, free fatty acids (FFA), HDL, low-density lipoproteins (LDL), lipoprotein (a) (Lp(a)), apolipoprotein AI (apoAI) and apoB were slight to significantly decreased, however, in some cases plasma levels of TG and Lp(a) might be increased. It has been suggested that analysis of plasma levels of lipids, lipoproteins and apolipoproteins in the patients suffered from HCC reflects on the hepatic cellular impairment status. Studies revealed that alterations seen in the plasma levels of lipids, lipoproteins and apolipoproteins reflecting patients' pathologic conditions. Decreased serum levels of cholesterol and apoAI may indicate a poor prognosis. Human leukaemic cells and certain tumor tissues have a higher receptor-mediated uptake of HDL and LDL than the corresponding normal cells or tissues. LDL and HDL have therefore been proposed as a carrier for the water-insoluble anti-cancer agents.

Citing Articles

Scoring System for Predicting the Risk of Liver Cancer among Diabetes Patients: A Random Survival Forest-Guided Approach.

Yau S, Leung E, Hung C, Wong M, Chong K, Lee A Cancers (Basel). 2024; 16(13).

PMID: 39001373 PMC: 11240698. DOI: 10.3390/cancers16132310.


Identification of Plasma Lipid Alterations Associated with Melanoma Metastasis.

Szasz I, Koroknai V, Varvolgyi T, Pal L, Szucs S, Piko P Int J Mol Sci. 2024; 25(8).

PMID: 38673837 PMC: 11050015. DOI: 10.3390/ijms25084251.


Effect of Shan Zha (Hawthorn or Crataegus) on gastrointestinal cancer: A network pharmacology and molecular docking study.

Yang J, Gu J, Shen Y, Cao L, Zhou H, Zhu W Cancer Pathog Ther. 2024; 1(4):229-237.

PMID: 38327605 PMC: 10846330. DOI: 10.1016/j.cpt.2023.02.001.


Targeted Analysis of Glycerophospholipids and Mono-, Di-, or Tri-Acylglycerides in Liver Cancer.

Chen H, Durand S, Bourgin M, Lambertucci F, Motino O, Montegut L Methods Mol Biol. 2024; 2769:189-198.

PMID: 38315398 DOI: 10.1007/978-1-0716-3694-7_14.


PanomiR: a systems biology framework for analysis of multi-pathway targeting by miRNAs.

Yeganeh P, Teo Y, Karagkouni D, Pita-Juarez Y, Morgan S, Slack F Brief Bioinform. 2023; 24(6).

PMID: 37985452 PMC: 10661971. DOI: 10.1093/bib/bbad418.


References
1.
Wasan K, MORTON R . Differences in lipoprotein concentration and composition modify the plasma distribution of free and liposomal annamycin. Pharm Res. 1996; 13(3):462-8. DOI: 10.1023/a:1016065114515. View

2.
James N, Gill J, Brindle R, Woodyatt N, Macdonald N, Rolfe M . Peroxisome proliferator-activated receptor (PPAR) alpha-regulated growth responses and their importance to hepatocarcinogenesis. Toxicol Lett. 1999; 102-103:91-6. DOI: 10.1016/s0378-4274(98)00291-4. View

3.
Navasa M, Gordon D, Hariharan N, Jamil H, Shigenaga J, Moser A . Regulation of microsomal triglyceride transfer protein mRNA expression by endotoxin and cytokines. J Lipid Res. 1998; 39(6):1220-30. View

4.
Hiraoka H, Yamashita S, Matsuzawa Y, Kubo M, Nozaki S, Sakai N . Decrease of hepatic triglyceride lipase levels and increase of cholesteryl ester transfer protein levels in patients with primary biliary cirrhosis: relationship to abnormalities in high-density lipoprotein. Hepatology. 1993; 18(1):103-10. View

5.
Chu A, Tsang S, Lo E, Fung K . Low density lipoprotein as a targeted carrier for doxorubicin in nude mice bearing human hepatoma HepG2 cells. Life Sci. 2002; 70(5):591-601. DOI: 10.1016/s0024-3205(01)01441-2. View